BioHealth Innovation, Inc. (BHI), a leading public-private nonprofit organization dedicated to advancing healthcare innovation in the BioHealth Capital Region, is pleased to announce the appointment of two new members to its Board of Directors: Amy Adams, Executive Director of the Institute for Biohealth Innovation at George Mason University, and Dr. Jessica Nadler, Managing Director at Deloitte. These new appointments reflect BHI’s continued commitment to building a diverse and strategically aligned leadership team to guide the organization’s mission of supporting innovation and entrepreneurship in the life sciences.
Amy Adams brings more than two decades of experience in higher education, with a deep focus on research, innovation, and workforce development. As Executive Director of the Institute for Biohealth Innovation at George Mason University, she leads the biohealth research and innovation efforts of over 300 faculty and plays a central role in developing Northern Virginia’s first Innovation District. Her work fosters partnerships across academia, industry, and government to accelerate biomedical innovation, support startups, and grow high-quality jobs across strategic sectors including life sciences, defense, and data infrastructure.
Dr. Jessica Nadler offers a wealth of expertise in data-informed health strategy, policy, and systems transformation. As a Managing Director at Deloitte, she helps shape the future of healthcare by focusing on translational medicine, patient-centered care, and public health portfolio strategy. Dr. Nadler’s background includes faculty service as a geneticist at the University of North Carolina at Chapel Hill and a fellowship in Science & Technology Policy at the U.S. Department of Health & Human Services through the American Association for the Advancement of Science.
“We are honored to welcome Amy and Jessica to the BHI Board,” said Rich Bendis, Founder, President, and CEO of BioHealth Innovation. “Each brings valuable perspectives and experience that will help us continue building bridges across academia, industry, and government. Their leadership will be instrumental as we grow BHI’s impact both regionally and nationally.”
BHI also thanks Juergen Klenk, Principal at Deloitte Consulting, LLP, for his valuable service on the Board and extends best wishes as he enters retirement. BHI also thanks Dr. Michael Friedlander, Vice President for Health Sciences and Technology at Virginia Tech, for his years of dedicated service as a member of the Board. His contributions have helped shape BHI’s strategic direction and foster deeper collaboration across the BioHealth Capital Region.
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc. (BHI) is a public-private nonprofit organization dedicated to accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC, and Virginia). For more information, please visit www.BioHealthInnovation.org.